Helping Cancer Patients Manage Neuropathy Symptoms From Chemotherapy With a Low-Intensity, Low-Risk Cranial PEMF Device

Launched by FLUXWEAR, INC · Jun 30, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Able to use smart phone and willing to receive text messages/emails
• • Has CIPN disorder/neuropathic pain related to chemotherapy
• • Able and willing to follow instructions
• • Not participated in any other clinical study within the past two months that may influence the results of this study
• Exclusion Criteria:
• • History of seizures
• • Hydrocephalic
• • Had a change in medical therapy related to the treatment of neuropathy or chronic pain in the last fourteen days
• • Received repetitive transcranial magnetic stimulation (rTMS) in the last 60 days
• • Implanted device or metal in the brain
• • History of brain bleed in the last six months
• • History of suicidal behavior, bipolar disorder, schizophrenia
• • Active radiation over the scalp
• • Brain metastases
• • Currently participates in other neuropathic pain studies
• • Has any other medical condition that would prevent them from participating, including scalp wounds, hyperhidrosis, sensitive scalp, rash
• • Pregnant